$0.73
0.00 (-0.67%)
Open$0.74
Previous Close$0.73
Day High$0.75
Day Low$0.73
52W High$2.35
52W Low$0.53
Volume—
Avg Volume1.98M
Market Cap162.97M
P/E Ratio—
EPS$-0.47
SectorBiotechnology
Analyst Ratings
Strong Buy
13 analysts
Price Target
+4,865.0% upside
Current
$0.73
$0.73
Target
$36.15
$36.15
$26.32
$36.15 avg
$48.95
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 59.14M | 52.95M | 62.98M |
| Net Income | 4.93M | 4.47M | 5.16M |
| Profit Margin | 8.3% | 8.4% | 8.2% |
| EBITDA | 5.59M | 4.86M | 6.72M |
| Free Cash Flow | 3.58M | 3.18M | 3.67M |
| Rev Growth | +23.4% | +5.7% | +6.5% |
| Debt/Equity | 0.46 | 0.42 | 0.50 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.46 | -0.54% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $415.21 | -0.63% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $138.36 | +0.16% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $505.75 | -2.07% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $803.48 | -0.31% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.65 | +0.67% | 35.2 | 28.41B |